CD274 and neoplasm: Anti-PD1/PDL1 therapies have shown remarkable efficacy in multiple tumor types, but their effectiveness is largely limited to patients with high PD-L1 expression prior to treatment, leaving a significant portion of the patient population in need of alternative immune checkpoint inhibitors.